BACKGROUND: Leishmaniasis is endemic in 88 countries in the world, and 350 million individuals are at risk of acquiring the disease. Treatment for American cutaneous leishmaniasis (ACL) is long, expensive, and associated with important side-effects. METHODS: In this double-blind, placebo-controlled study, we treated 102 patients with ACL using either a combination of asingle-strain Leishmania amazonensis killed promastigote vaccine plus a half dose of meglumine antimoniate, or placebo plus the same half dose regimen of meglumine antimoniate, in 10-day series followed by 10-day intervals. RESULTS: Of the 47 patients in the experimental arm, 47 (100%) were cured after four series of treatment, compared to four of 49 (8.2%) in the control group (P < 0.0001). Six patients were lost to follow-up. CONCLUSIONS: The combination of a single-strain Leishmania (Leishmania) amazonensis killed promastigote vaccine with a half dose regimen of antimonial is highly effective for the treatment of ACL.
RCT Entities:
BACKGROUND:Leishmaniasis is endemic in 88 countries in the world, and 350 million individuals are at risk of acquiring the disease. Treatment for American cutaneous leishmaniasis (ACL) is long, expensive, and associated with important side-effects. METHODS: In this double-blind, placebo-controlled study, we treated 102 patients with ACL using either a combination of a single-strain Leishmania amazonensis killed promastigote vaccine plus a half dose of meglumine antimoniate, or placebo plus the same half dose regimen of meglumine antimoniate, in 10-day series followed by 10-day intervals. RESULTS: Of the 47 patients in the experimental arm, 47 (100%) were cured after four series of treatment, compared to four of 49 (8.2%) in the control group (P < 0.0001). Six patients were lost to follow-up. CONCLUSIONS: The combination of a single-strain Leishmania (Leishmania) amazonensis killed promastigote vaccine with a half dose regimen of antimonial is highly effective for the treatment of ACL.
Authors: E Telino; P M De Luca; D C S Matos; R B Azeredo-Coutinho; M N Meirelles; F Conceição-Silva; A Schubach; S C F Mendonça Journal: Clin Exp Immunol Date: 2006-02 Impact factor: 4.330
Authors: Douglas R Rice; Paola Vacchina; Brianna Norris-Mullins; Miguel A Morales; Bradley D Smith Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191
Authors: Sandra R Afonso-Cardoso; Flavio H Rodrigues; Marcio A B Gomes; Adriano G Silva; Ademir Rocha; Aparecida H B Guimaraes; Ignes Candeloro; Silvio Favoreto; Marcelo S Ferreira; Maria A de Souza Journal: Korean J Parasitol Date: 2007-12 Impact factor: 1.341
Authors: Brima M Younis; Mohamed Osman; Eltahir A G Khalil; Francesco Santoro; Simone Furini; Rebecca Wiggins; Ada Keding; Monica Carraro; Anas E A Musa; Mujahid A A Abdarahaman; Laura Mandefield; Martin Bland; Toni Aebischer; Rhian Gabe; Alison M Layton; Charles J N Lacey; Paul M Kaye; Ahmed M Musa Journal: Mol Ther Date: 2021-03-27 Impact factor: 11.454